Chronic Obstructive Pulmonary Disease – Pipeline Review, H1 2017
- Pages: 466
- Published: May 2017
- Report Code: GMDHC9293IDB
Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2017’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects
The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abeona Therapeutics Inc
Achillion Pharmaceuticals Inc
Adamis Pharmaceuticals Corp
Advanced Inhalation Therapies (AIT) Ltd
Advinus Therapeutics Ltd
AlgiPharma AS
Allinky Biopharma
Alteogen Inc
Amakem NV
Angiocrine Bioscience Inc
Angion Biomedica Corp
apceth Biopharma GmbH
Apellis Pharmaceuticals Inc
Aridis Pharmaceuticals LLC
Astellas Pharma Inc
AstraZeneca Plc
Asubio Pharma Co Ltd
Axikin Pharmaceuticals Inc
Bayer AG
Beech Tree Labs Inc
Bioneer Corp
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Carolus Therapeutics Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Ltd
Cytokinetics Inc
Daiichi Sankyo Company Ltd
Diffusion Pharmaceuticals Inc
Domainex Ltd
Enterprise Therapeutics Ltd
Errant Gene Therapeutics LLC
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Galapagos NV
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Grifols SA
Hanmi Pharmaceuticals Co Ltd
iCeutica Inc
InMed Pharmaceuticals Inc
Innate Pharma SA
Insmed Inc
Intech Biopharm Ltd
Invion Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
KaloBios Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
Medestea Research & Production SpA
MedImmune LLC
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Microbion Corp
Novartis AG
Odan Laboratories Ltd
OPKO Health Inc
Orchid Pharma Ltd
Orion Oyj
Pfizer Inc
Pharmaxis Ltd
Promedior Inc
ProMetic Life Sciences Inc
Proteostasis Therapeutics Inc
Pulmagen Therapeutics LLP
Pulmatrix Inc
Qu Biologics Inc
Quark Pharmaceuticals Inc
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Respira Therapeutics Inc
Respiratorius AB
rEVO Biologics Inc
Rhizen Pharmaceuticals SA
SATT North SAS
Seoul Pharma Co Ltd
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Synedgen Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Company Ltd
Teva Pharmaceutical Industries Ltd
Therabron Therapeutics Inc
Theravance Biopharma Inc
Torrent Pharmaceuticals Ltd
Unizyme Laboratories A/S
Vectura Group Plc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
Yuhan Corp
Yungjin Pharm Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.